+ Filter
Loading...
Custom Services order now ship next day

Anti-KRAS Recombinant Antibody Products

Loading...

Anti-KRAS Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs offers a premier selection of innovative recombinant antibodies targeting KRAS, playing a vital role in advancing biomedical science. Through the use of cutting-edge technology platforms, we ensure that each product adheres to rigorous standards of quality, consistency, and performance. Our extensive catalog reflects our unwavering commitment to driving scientific progress, with each antibody solution engineered for outstanding reliability and value. In addition to delivering top-tier reagents, we provide expert technical support to guide researchers throughout their experimental journey. Partnering with Creative Biolabs means accessing not only advanced tools but also a trusted ally committed to the success of your research.

KRAS: A Pivotal Target in Cancer Progression and Precision Oncology

KRAS is a well-established oncogene that plays a critical role in the development and progression of various cancers, including pancreatic, colorectal, and non-small cell lung cancer. As part of the RAS family of GTPases, KRAS regulates essential cellular functions such as proliferation, differentiation, and survival. Mutations in the KRAS gene often lead to uncontrolled cell signaling, contributing to tumor growth and resistance to therapy. Due to its high mutation frequency and central role in oncogenic pathways, KRAS has become a major focus in cancer research and drug development. Targeting KRAS-driven signaling offers promising therapeutic potential, particularly in tumors previously considered undruggable.

Alternative Names

Complement NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2

Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

Anti-KRAS rAb Products

We are dedicated to accelerating scientific advancement by providing premium anti-KRAS recombinant antibodies, combining exceptional performance, cost-effectiveness, and reliable technical guidance. Our goal is to empower researchers with the tools and support they need to drive meaningful discoveries.

Cat. No. Product Name Target Species Host Species Applications
HPAB-N0159-YC Human Anti-KRAS Recombinant Antibody (HPAB-N0159-YC) Human Human ELISA
MOB-1225z Mouse Anti-KRAS Recombinant Antibody (clone 23A6) Human Mouse WB; ELISA; FC; ICC; IF
MOB-1757MZ Recombinant Mouse Anti-Human KRAS Antibody Human Mouse FC; IHC-P; WB
MOR-0031-FY Rabbit Anti-KRAS Recombinant Antibody (clone AFY0002) Human Rabbit IHC-P; WB

Customer Reviews

Excellent
A**on
Mouse Anti-KRAS Recombinant Antibody (clone 23A6) (CAT#: MOB-1225z)
Used it for Western blot on A549 cell lysates. Clear, specific bands with minimal background. Also tested in flow cytometry on HCT116 cells with decent signal. Overall, a reliable antibody for basic KRAS detection work.
12/Feb/2023
Excellent
M**ez
Recombinant Mouse Anti-Human KRAS Antibody (CAT#: MOB-1757MZ)
Evaluated its performance in Western blot as well as flow cytometry. Used A549 and HCT116 cell lines for validation. In Western blot, the antibody produced clear bands at the expected size with low background. For flow cytometry, the signal was detectable and consistent, though some optimization was needed for staining conditions. Overall, the antibody performed reliably for basic applications. Good option for routine KRAS detection, but make sure to validate conditions for your specific setup.
15/Aug/2024

rAb Production

With years of experience in developing and optimizing recombinant antibodies, we are able to offer high-quality products with consistent performance. Our efficient processes and commitment to excellence ensure timely delivery and dependable service tailored to researchers' needs.

Featured Anti-KRAS Recombinant Antibody Production PlatformsAnti-KRAS recombinant antibody production: milligram-scale. (Creative Biolabs Original)
Fig.1 Milligram-scale recombinant antibody production.

Anti-KRAS recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.2 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs is committed to providing researchers with a diverse selection of cutting-edge recombinant antibodies in multiple formats. With extensive expertise in recombinant antibody technologies, we employ a variety of advanced engineering techniques. Additionally, we offer exceptional custom engineering services designed to meet the unique requirements of your research.

Diverse anti-KRAS recombinant antibody production and modalities. (Creative Biolabs Original)Fig.3 Full Length Anti-KRAS Recombinant Antibody Production and Modalities.

Drug Information Targeting KRAS

Table 1. Therapeutic approaches targeting KRAS in clinical development.

Research phase Company Classification Indications Details
Phase II Gritstone bio Biologics Cancer It is an optimized neoantigen immunotherapy targeting mutated KRAS, developed by Gritstone bio and currently under phase II evaluation for KRAS-mutant non-small cell lung and colorectal cancers.
Phase II Silenseed Biologics Cancer It is a biodegradable RNA-based therapy targeting KRASG12D, developed by Silenseed for unresectable pancreatic cancer and currently in phase II trials, with orphan drug status granted by the FDA in 2015.
Phase I/II Mirati Therapeutics Small Molecules Cancer; Solid tumor It is an oral small-molecule SOS1 inhibitor developed by Mirati Therapeutics, now part of Bristol-Myers Squibb, for treating KRAS- or MAPK-driven solid tumors, currently in early clinical development.
Phase I/II Mirati Therapeutics Small Molecules Cancer; Solid tumor It is an oral small-molecule inhibitor of KRASG12D developed by Mirati Therapeutics for advanced solid tumors, including NSCLC, CRC, and pancreatic cancer, with selectivity demonstrated in preclinical studies.
Phase I/II Elicio Therapeutics Drug Conjugates Cancer; Solid tumor It is a cancer vaccine developed by Elicio Therapeutics for KRAS-driven solid tumors in patients with minimal residual disease after surgical resection, currently in early clinical development.
Phase I Chugai Pharmaceutical Peptides Cancer; Solid tumor It is an oral RAS inhibitor developed by Chugai for the treatment of locally advanced or metastatic solid tumors, currently in early clinical development.
Phase I Jiangsu Hengrui Others Cancer; Solid tumor It is a KRAS G12D-targeting therapy developed by Jiangsu Hengrui, currently being assessed in early clinical trials for advanced solid tumors.
Phase I Revolution Medicines Small Molecules Cancer; Solid tumor It is a covalent and mutant-selective KRASG12D(ON) inhibitor developed by Revolution Medicines, currently in phase I trials for the treatment of KRASG12D-mutant solid tumors.
Phase I Astellas Pharma Others Cancer; Solid tumor It is a small-molecule KRAS G12D degrader developed by Astellas Pharma, currently in early clinical trials for advanced solid tumors, with FDA fast track designation granted in 2023 for pancreatic, colorectal, and non-small cell lung cancers.
Phase I RasCal Therapeutics Others Cancer; Solid tumor It is an oral small-molecule KRAS inhibitor targeting both wild-type and mutant forms, developed by RasCal Therapeutics for advanced solid tumors and currently in early clinical development.

If you need further details about the KRAS target, don't hesitate to contact us by phone or email. Our expert team is happy to help with any questions or issues you may encounter in your research, providing the support you need for a successful outcome.

Go to compare

Go to compare